Context: Individuals with metabolically healthy or benign obesity vs. unhealthy or at risk obesity have been distinguished; however, the predisposing factors for developing these phenotypes are poorly understood.
A lthough obesity commonly clusters with other cardiovascular risk factors (1), a significant proportion of obese individuals remain metabolically healthy, possessing few traditional cardiometabolic risk factors or maintaining insulin sensitivity compared with metabolically unhealthy or at-risk obese individuals (2) (3) (4) . In a recent report, at-risk obese individuals had rates of incident cardiovascular disease that were more than two times higher than in metabolically benign obese and healthy normal-weight individuals (5) . To date, factors accounting for developing at-risk vs. benign obese and healthy normal-weight phenotypes are poorly understood, leaving many unanswered questions regarding why some obese individuals experience greater cardiometabolic risk despite similar excesses in weight.
Pubertal timing has important implications for cardiovascular and breast cancer risk in adulthood (6) . With respect to cardiometabolic outcomes in particular, earlier pubertal onset has been related to risk for accelerated postpubertal weight gain, incident cardiovascular events, and higher cardiac-specific and all-cause mortality (7) (8) (9) (10) (11) (12) , yet whether it also confers risk for developing metabolically unhealthy obesity has not been studied. Earlier pubertal onset may be linked to the at-risk obesity phenotype via hyperandrogenemia. Androgens are commonly elevated in the obese state (13) , including among obese peripubertal girls (14) . In addition, higher prepubertal androgen levels have predicted earlier pubertal development in girls, independently of anthropometric indicators (i.e. birth weight, fat mass, and maternal overweight) (15) , and among adult women, higher androgen levels correlated with cardiovascular risk factors, independently of body mass index (BMI) (16) . On this basis, we hypothesized that earlier sexual maturation may promote an obesity phenotype associated with increased cardiometabolic risk, possibly due to concomitant elevations in androgens.
In a multiethnic sample of 989 premenopausal women, the aims of the current study were 1) to examine pubertal timing marked by menarcheal age in relation to at-risk obese, benign obese, and healthy normal-weight phenotypes at midlife and 2) to characterize the potential role of androgens in accounting for any associations between menarcheal age and obesity phenotype.
Subjects and Methods

Participants
Women in the current sample were participants in the Ovarian Aging (OVA) Study, an investigation of reproductive health and aging. Participants were recruited through Kaiser Permanente of Northern California, an integrated healthcare delivery system that provides medical care to approximately one third of the population of Northern California. Selection criteria were age 25-45 yr, regular menses, having a uterus and both ovaries, and self-identification as Caucasian, African-American, Latina, Chinese, or Filipina. Exclusions were major medical illnesses, use of medications affecting the menstrual cycle within the 3 months before study participation, and pregnancy/breastfeeding. The protocol included a medical history interview, transvaginal ultrasound, anthropometric assessment, and blood draw. Of 1019 total participants, 989 women with complete data on the relevant variables were retained. The study protocol was approved by the University of California San Francisco and Kaiser Permanente of Northern California Institutional Review Boards. Informed, written consent was obtained from all study participants.
Group classifications
Women were categorized into healthy normal-weight, benign obese, and at-risk obese groups. Healthy normal weight was defined as having a BMI between 18.5 and 24.9 kg/m 2 and no more than one metabolic syndrome component: 1) triglycerides 150 mg/dl or higher, 2) high-density lipoprotein (HDL) below 50 mg/dl and/or use of lipid-lowering medication, 3) glucose 100 mg/dl or higher, or 4) self-reported diagnosis of hypertension and/or use of antihypertensive medication. Benign obese was defined as having a BMI of at least 30 kg/m 2 and no more than one metabolic syndrome component. At-risk obese was defined as having a BMI of at least 30 kg/m 2 and at least two metabolic syndrome components. Underweight, overweight, and normalweight women with two or more metabolic syndrome components were excluded. Definitions were adapted from a commonly used classification in which healthy normal-weight and benign obese is defined as having no more than two and at-risk obese is defined as having at least three metabolic syndrome components (5) because of the low frequency of women in the current sample with three or more metabolic syndrome components.
Measures
Menarcheal age
As a part of a medical history interview, women were asked to report the age of their first menstrual period. Retrospective reports of menarcheal age have been shown to be highly reliable (17) .
Anthropometric measures and components of metabolic syndrome
A study nurse performed an anthropometric assessment to determine BMI (weight in kilograms/height in meters squared), waist circumference, and waist-to-hip ratio. Quest Diagnostics (San Jose, CA) performed assays for triglycerides [intraassay coefficient of variation (CV) ϭ 1.99 -3.45%) and HDL (intraassay CV ϭ 1.15-2.02%) using enzymatic methods and fasting glucose (intraassay CV ϭ 1.25-2.00%) using the glucose oxidase method. Previously diagnosed hypertension (yes/no) and/or use of antihypertensive medications (yes/no) was used as a surrogate for elevated systolic/diastolic blood pressure.
Androgen levels
Androgen levels were indexed by the free androgen index (FAI), calculated as testosterone/SHBG ϫ 100 to estimate the quantity of unbound or biologically active testosterone. Testosterone (intraassay CV ϭ 2.9 -4.0%; interassay CV ϭ 6.3-6.6%) and SHBG (intraassay CV ϭ 6.4 -7.0%; interassay CV ϭ 6.9 -8.9%) were assayed with an automated chemiluminescent assay using the Bayer Diagnostics ACS:180 (Bayer Diagnostics Corp., Tarrytown, NY). The testosterone assay was modified to increase precision at low ranges by increasing the sample volume while reoptimizing reagent volumes. Specificity of this assay is high as demonstrated by limited cross-reactivity of closely related steroids.
Statistical analysis
Two multinomial logistic regression models were evaluated. First (model 1), menarcheal age was examined in relation to the probability of being in either the benign obese or the at-risk obese group compared with the healthy normal-weight group as well as the probability of being in the at-risk obese compared with the benign obese group. Next (model 2), FAI was added to the model to evaluate whether associations between menarcheal age and group membership (if present) were independent of androgen levels. In all models, covariates included age, race/ethnicity (rep-resented by four dummy-coded variables with Caucasian as the reference), level of education, household income divided by the number of individuals dependent on the reported income, smoking (1 ϭ current/past smoking; 0 ϭ never smoked), past use of a hormonal method of contraception (0 ϭ no history of use; 1 ϭ positive history of use), parity (0 ϭ no live births; 1 ϭ one or more live births), physical activity level [indexed by metabolic equivalent (MET) hours of moderate/vigorous activity in a typical week] (18), and self-reported weight at age 18.
Results
Sample characteristics
Among 989 women, the mean age was 35.2 (SD ϭ 5.5). The racial/ethnic composition included 28.0% Caucasian, 23.7% African-American, 22.5% Latina, 21.7% Chinese, and 4.1% Filipina. Of these women, 447 were categorized as healthy normal weight, 184 were categorized as benign obese, and 73 were categorized as at-risk obese. Exclusions included 23 underweight women, 252 overweight women, and 10 normal-weight women who had at least two components of metabolic syndrome.
Age-adjusted correlations in the full cohort (n ϭ 989) showed menarcheal age was related to SHBG (r ϭ 0.120; P ϭ 0.000) and FAI (r ϭϪ0.117; P ϭ 0.000) but not to testosterone (r ϭ -0.033; P ϭ 0.303). Descriptive information for healthy normal-weight (n ϭ 447), benign obese (n ϭ 184), and at-risk obese (n ϭ 73) groups is reported in Table 1 . Normal-weight women were significantly b Significant differences were between normal-weight and at-risk obese. c Significant differences were between benign obese and at-risk obese.
d Education was coded as 1 ϭ less than high school/some high school; 2 ϭ high school grad/general equivalency diploma (GED); 3 ϭ some college/associate degree/vocational school; 4 ϭ college graduate; younger than women in the benign and at-risk obese groups (P Ͻ 0.001). Socioeconomic status was higher, nulliparity was more common, and menarcheal age was older in the normal-weight women compared with the benign and at-risk obese groups (P Ͻ 0.001). All groups were significantly different from one another on the variables used to determine group membership (BMI, triglycerides, HDL, glucose, and hypertensive status) (all P Ͻ 0.001). SHBG was higher in the normal-weight compared with the benign and at-risk obese groups (P Ͻ 0.001), and FAI was different between all groups with levels progressively increasing across normal-weight, benign obese, and at-risk obese groups (P Ͻ 0.001).
Multinomial logistic regression
Results of multinomial logistic regression analyses are reported in Table 2 . In model 1, results showed that with each year menarcheal age is delayed, the probability of being in the at-risk obese compared with the normalweight group was reduced by 22.2% [odds ratio (OR) ϭ 0.778; 95% confidence interval (CI) ϭ 0.631-0.958]. In model 2, this association attenuated to the level of a statistical trend when FAI was entered in the model (OR ϭ 0.818; 95% CI ϭ 0.656 -1.022), suggesting the effect of menarcheal age on group membership is partially attributable to levels of FAI. In both models 1 and 2, older age, African-American, Latina, and Filipina race/ethnicity, lower education, and higher self-reported weight at age 18 were independently associated with an increased probability of being in the at-risk compared with the normalweight group, whereas African-American race/ethnicity and past use of a hormonal method of contraception were independentlyassociatedwithanincreasedprobabilityofbeingin the at-risk compared with benign obese group. In addition, a one-unit increase in FAI was related to a 2.2% increased probability of being in the at-risk obese compared with the normal weight group and a 0.3% increased probability of being in the at-risk compared with benign obese group.
Discussion
Each 1-yr increase in menarcheal age was associated with a 22% reduction in the probability of having the at-risk obese compared with the healthy normal-weight phenotype; however, this association substantially attenuated when FAI was covaried, suggesting the association between menarcheal age and the at-risk obese phenotype was driven by androgen levels. Older age, African-American, Latina, and Filipina race/ethnicity, lower education, and higher weight at age 18 were independently related to the at-risk obese compared with the healthy normalweight phenotype, whereas African-American race/ethnicity and past use of a hormonal method of contraception were independently related to the at-risk obese compared with the benign obese phenotype.
Notably, higher FAI was independently related to the at-risk obese compared with the healthy normal-weight phenotype as well as the at-risk obese compared with the benign obese phenotype. Lower SHBG, which is common in individuals with higher BMI (16), did not account for the higher FAI values observed in the at-risk compared with benign obese phenotype. Rather, results of descriptive analyses showed that mean levels of SHBG, as well as testosterone, were not statistically different between these groups. This highlights the significance of understanding the unique role of unbound or biologically active testosterone (measured as the proportion of testosterone to SHBG) vs. the absolute levels of these hormones. Implications of the current study are that earlier pubertal onset via elevated androgen levels may promote an obesity phenotype associated with increased cardiometabolic risk. These findings may help characterize obese women at greatest cardiometabolic risk so that preventive intervention efforts may be specifically targeted to this subgroup, an important goal in light of the continuing obesity epidemic (19) and modest successes of existing approaches to weight loss (20) .
Future research efforts should improve upon the weaknesses of the current study by 1) including a measure of childhood obesity, a known influence on pubertal timing; 2) employing longitudinal study designs that address the temporal associations between pubertal timing, androgen levels, and the future development of at-risk or benign obesity phenotypes; 3) using a direct measure of free testosterone; 4) screening for nonclassical 21-hydroxylase deficiency, a condition of subtle androgen excess that is associated both with earlier pubertal onset and metabolic syndrome; 5) examining the association of menarcheal age with cardiometabolic risk among normal-weight women (only 10 normal-weight women in the current sample had two or more cardiometabolic risk factors); and 6) fully elucidating the potential confounders and/or underlying mechanisms by which earlier pubertal onset is associated with a hormonal environment linked to increased cardiometabolic risk.
